Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Regeneron Pharmaceuticals Inc. buy BMO Capital Markets

Regeneron Pharmaceuticals Inc.
Start price
€858.00
05.02.24 / 50%
Target price
€1,006.8
05.02.25
Performance (%)
-19.14%
End price
€693.80
06.02.25
Summary
This prediction ended on 06.02.25 with a price of €693.80. The price of Regeneron Pharmaceuticals Inc. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -19.14%. BMO_Capital_Markets has a follow-up prediction for Regeneron Pharmaceuticals Inc. where he still thinks Regeneron Pharmaceuticals Inc. is a Buy. BMO_Capital_Markets has 50% into this prediction

Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.

Performance without dividends (%)
Name 1w 1m 1y
Regeneron Pharmaceuticals Inc. 2.606% 2.606% -53.722%
iShares Core DAX® 0.648% 1.259% 33.177%
iShares Nasdaq 100 -0.034% 2.797% 14.536%
iShares Nikkei 225® 2.445% 9.854% 9.686%
iShares S&P 500 0.492% 2.570% 10.401%

Comments by BMO_Capital_Markets for this prediction

In the thread Regeneron Pharmaceuticals Inc. diskutieren
Prediction Buy
Perf. (%) -19.14%
Target price 1006.801
Change
Ends at 05.02.25

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target raised by analysts at BMO Capital Markets from $1,055.00 to $1,082.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat

BMO Capital Markets 
0
Report Share
05.02.24
In the thread Trading Regeneron Pharmaceuticals Inc.
Prediction Buy
Perf. (%) -19.14%
Target price 1006.801
Change
Ends at 05.02.25

Die von BMO_Capital_Markets gewählte maximale Laufzeit wurde überschritten

BMO Capital Markets 
0
Report Share
06.02.25

Current prediction by BMO_Capital_Markets for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€939.20
24.09.24
€1,165.3
24.09.25
-47.00%
15.08.25

BMO Capital Markets 
24.09.24 50%

Stopped prediction by BMO_Capital_Markets for Regeneron Pharmaceuticals Inc.

buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€494.10
04.08.25
€552.90
04.08.26
0.40%
15.08.25

BMO Capital Markets 
04.08.25 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€427.60
02.06.25
€527.70
02.06.26
16.02%
15.08.25

BMO Capital Markets 
02.06.25 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€515.60
30.04.25
€703.60
30.04.26
-3.61%
15.08.25

BMO Capital Markets 
30.04.25 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€681.40
04.02.25
€869.77
04.02.26
-26.94%
15.08.25

BMO Capital Markets 
04.02.25 50%
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€779.00
01.11.24
€1,096.8
01.11.25
-36.10%
15.08.25

BMO Capital Markets 
01.11.24 50%